Hibiscus Bioventures

Hibiscus Bioventures, founded in 2019 and based in Rockville, Maryland, is a startup studio and venture capital firm focused on the biotechnology and pharmaceutical sectors. The company specializes in identifying and nurturing innovative technologies and business models within these industries. In addition to its investment activities, Hibiscus Bioventures offers consultancy services tailored to corporate development and mergers and acquisitions, assisting companies in navigating the complexities of the biotechnology landscape. By leveraging its expertise, Hibiscus Bioventures aims to support the growth of transformative solutions that have the potential to advance healthcare and improve patient outcomes.

Cai Yaoting

Partner

3 past transactions

AsclepiX Therapeutics

Series A in 2023
AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for retinal diseases and certain cancers. The company specializes in designing short biomimetic peptides that target angiogenesis and lymphangiogenesis, utilizing advanced bioinformatics and systems biology approaches. Its lead product candidates, including AXT107, AXT201, AXT301, and AXT501, are aimed at addressing conditions such as diabetic macular edema, age-related macular degeneration, and macular edema from retinal vein occlusion, all of which are significant causes of blindness in the western world. Additionally, AXT201, AXT301, and AXT501 are in early development stages for treating various solid tumors. AsclepiX Therapeutics employs cutting-edge biomaterials and drug delivery systems, including biodegradable nano and microparticles, to enhance the therapeutic efficacy of its peptide-based treatments. Incorporated in 2011 and headquartered in Baltimore, Maryland, the company is leveraging its platform technology to advance solutions in both ophthalmology and oncology.

Leto Laboratories

Series C in 2022
Leto Laboratories is a research-focused organization dedicated to advancing the field of protein re-engineering to address unmet medical needs, particularly in cancer and rare diseases. The company utilizes cutting-edge technologies, including high-throughput protein re-screening, purification, and drug formulation development platforms, to facilitate the creation of innovative protein-based therapeutics. With a diverse team of experts, Leto Laboratories aims to enhance the efficacy of protein-based drugs and contribute significantly to the treatment landscape for challenging health conditions.

Cellevolve Bio

Seed Round in 2021
Cellevolve Bio is a development and commercialization company specializing in cell therapies aimed at neglected diseases. The company collaborates with innovators to transition early-stage clinical therapies into commercially available treatments, particularly for pediatric and rare diseases. By advancing these therapies into clinical development, Cellevolve aims to significantly enhance patient outcomes and provide expertise in cell therapy and clinical care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.